Immunohistochemical Evaluation of the Relationship of PTEN Gene Expression and Pathological Parameters in Patients with Breast Cancer

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anatomical Sciences, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

2 Assistant Professor, Department of Microbiology and Immunology, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

3 Associate Professor, Department of Physiological Sciences, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

4 Associate Professor, Department of Anatomical Sciences and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Genetic damages and epigenetic factors are important in invasive breast cancer. PTEN gene is one of the most important tumor suppressor genes. Phosphatase and tensin homolog (PTEN) protein can be traced by immunohistochemistry methods. The purpose of this study was to determine the relationship of PTEN gene expression and pathological parameters in patients with breast cancer.Methods: This descriptive analytical research was conducted on 100 cases with breast cancer admitted to a hospital in Sabzevar, Iran, during 2010-13. Samples were fixed in formalin; tissue processing and taking sections was done. Then, the slides were stained by hematoxylin and eosin. Malignancy was diagnosed by two pathologists blindly. Expression of PTEN gene was evaluated after antigen retrieval with primary specific rabbit monoclonal PTEN antibody using by immunohistochemical method. Photos were taken by light microscope. Data were analyzed using chi-square and Fisher’s exact tests.Findings: In 70 (70%) specimens, PTEN protein was detected. Protein stability was observed in total normal samples. No significant relationship was observed between the stage and grade of tumor, but there was significant relationship between PTEN gene expression and tumor grade and stage (P < 0.05). Over-expression of PTEN gene was lower in invasive ductal carcinoma compared to non-invasive breast cancers.Conclusion: Our study showed that PTEN gene expression is low in patients with high-grade breast tumors. Therefore, we may conclude that low expression of PTEN gene is accompanied with bad prognosis in patients with breast cancer.

Keywords

References

  1. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9(6): 606-16.
  2. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8(10): 843-54.
  3. Laurance J. Breast cancer cases rise 80% since Seventies. The independent Health & Wellbeing 2006; 9-29.
  4. Lam WW, Fielding R, Ho EY. Predicting psychological morbidity in Chinese women after surgery for breast carcinoma. Cancer 2005; 103(3): 637-46.
  5. Golmohammadi R, Pejhan A. The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. J Pak Med Assoc 2012; 62(9): 871-5.
  6. Kumar V, Abbas AK, Fausto N, Mitchell R. Robbins Basic Pathology. 8th ed. Cambridge, MA: Saunders; 2007.
  7. Golmohammadi R, Namazi MJ, Nikbakht M, Salehi M, Derakhshan MH. Characterization and Prognostic Value of Mutations in Exons 5 and 6 of the p53 Gene in Patients with Colorectal Cancers in Central Iran. Gut Liver 2013; 7(3): 295-302.
  8. Dastjerdi MN, Salahshoor MR, Mardani M, Rabbani M, Hashemibeni B, Gharagozloo M, et al. The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci 2013; 8(2): 79-89.
  9. de Assis LV, Isoldi MC. The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumour Biol 2014; 35(2): 889-901.
  10. Bogdanova N, Helbig S, Dork T. Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract 2013; 11(1): 12.
  11. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4(3): 209-21.
  12. Wan W, Zou H, Sun R, Liu Y, Wang J, Ma D, et al. Investigate the role of PTEN in chemotaxis of human breast cancer cells. Cell Signal 2007; 19(11): 2227-36.
  13. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 2009; 20(4): 648-54.
  14. Boosani CS, Agrawal DK. PTEN modulators: a patent review. Expert Opin Ther Pat 2013; 23(5): 569-80.
  15. Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, et al. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 2010; 18(4): 371-4.
  16. Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao W, et al. PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol 2010; 136(9): 1303-11.
  17. Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, et al. Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res 2012; 14(2): R49.
  18. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 2003; 63(19): 6357-62.
  19. van den Broek AJ, Broeks A, Horlings HM, Canisius SV, Braaf LM, Langerod A, et al. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. Breast Cancer Res Treat 2011; 130(2): 599-608.
  20. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002; 277(7): 5484-9.
  21. Zhang HY, Liang F, Jia ZL, Song ST, Jiang ZF. PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett 2013; 6(1): 161-8.
  22. Fata JE, Debnath S, Jenkins EC, Jr., Fournier MV. Nongenomic Mechanisms of PTEN Regulation. Int J Cell Biol 2012; 2012: 379685.
  23. Jones N, Bonnet F, Sfar S, Lafitte M, Lafon D, Sierankowski G, et al. Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer 2013; 133(2): 323-34.
  24. Kitagishi Y, Matsuda S. Redox regulation of tumor suppressor PTEN in cancer and aging (Review). Int J Mol Med 2013; 31(3): 511-5.
  25. Li Y, He L, Zeng N, Sahu D, Cadenas E, Shearn C, et al. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling regulates mitochondrial biogenesis and respiration via estrogen-related receptor alpha (ERRalpha). J Biol Chem 2013; 288(35): 25007-24.
  26. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13(5): 283-96.
  27. Henle SJ, Carlstrom LP, Cheever TR, Henley JR. Differential role of PTEN phosphatase in chemotactic growth cone guidance. J Biol Chem 2013; 288(29): 20837-42.
  28. Baig RM, Mahjabeen I, Sabir M, Masood N, Hafeez S, Malik FA, et al. Genetic changes in the PTEN gene and their association with breast cancer in Pakistan. Asian Pac J Cancer Prev 2011; 12(10): 2773-8.
Journal of Isfahan Medical School
Volume 32, Issue 282 - Serial Number 282
March and April 2014
Pages 514-523

Files

History

  • Receive Date: 30 November 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics